Table 1.
Association between clinical characteristics and JAG1 expression in cancer cells and endothelium
| Characteristics | JAG1 (cancer cells) | P‐value | JAG1 (endothelium) | P‐value | ||||
|---|---|---|---|---|---|---|---|---|
| Weak | Moderate | Strong | Weak | Moderate | Strong | |||
| Total | 51 (32) | 57 (36) | 50 (32) | 61 (39) | 54 (34) | 43 (27) | ||
| Sex | 0.352 | 0.877 | ||||||
| Male | 31 (61) | 36 (63) | 25 (50) | 36 (59) | 30 (56) | 26 (60) | ||
| Female | 20 (39) | 21 (37) | 25 (50) | 25 (41) | 24 (44) | 17 (40) | ||
| Age (years) | NS | NS | ||||||
| Mean ± SD | 64.7 ± 10.8 | 64.6 ± 11.8 | 62.1 ± 13.9 | 63.0 ± 12.3 | 63.1 ± 10.1 | 65.9 ± 14.3 | ||
| Histologic type | 0.031* | 0.495 | ||||||
| Well differentiated | 38 (79) | 34 (61) | 26 (55) | 41 (71) | 32 (62) | 25 (61) | ||
| Moderate/Poorly | 10 (21) | 22 (39) | 21 (45) | 17 (29) | 20 (38) | 16 (39) | ||
| Others | 3 | 1 | 3 | 3 | 2 | 2 | ||
| T stage | 0.003** | 0.080 | ||||||
| T1 | 14 (27) | 8 (14) | 2 (4) | 15 (25) | 6 (11) | 3 (7) | ||
| T2 | 6 (12) | 7 (12) | 8 (16) | 5 (8) | 6 (11) | 10 (23) | ||
| T3 | 29 (57) | 31 (55) | 26 (53) | 32 (54) | 32 (59) | 22 (51) | ||
| T4 | 2 (4) | 11 (19) | 13 (27) | 8 (13) | 10 (19) | 8 (19) | ||
| Unknown | 1 | 1 | ||||||
| Lymph node metastasis | 0.242 | 0.035* | ||||||
| Negative | 33 (65) | 28 (49) | 26 (53) | 40 (67) | 23 (43) | 24 (56) | ||
| Positive | 18 (35) | 29 (51) | 23 (47) | 20 (33) | 31 (57) | 19 (44) | ||
| Unknown | 1 | 1 | ||||||
| Stage of tumor | 0.126 | 0.114 | ||||||
| 0–I | 18 (35) | 12 (21) | 7 (14) | 20 (33) | 6 (11) | 11 (25) | ||
| II | 12 (24) | 14 (25) | 15 (30) | 16 (26) | 13 (24) | 12 (28) | ||
| III | 15 (29) | 23 (40) | 15 (30) | 17 (28) | 22 (41) | 14 (33) | ||
| IV | 6 (12) | 8 (14) | 13 (26) | 8 (13) | 13 (24) | 6 (14) | ||
| Lymphatic invasion | 0.136 | 0.436 | ||||||
| Negative | 39 (76) | 34 (60) | 31 (62) | 43 (70) | 32 (59) | 29 (67) | ||
| Positive | 12 (24) | 23 (40) | 19 (38) | 18 (30) | 22 (41) | 14 (33) | ||
| Venous invasion | 0.818 | 0.039* | ||||||
| Negative | 32 (63) | 33 (58) | 27 (54) | 39 (64) | 24 (44) | 29 (67) | ||
| Positive | 19 (37) | 24 (42) | 23 (46) | 22 (36) | 30 (56) | 14 (33) | ||
| JAG1 (Endothelium) | <0.001** | JAG1 (Cancer) | <0.001** | |||||
| Weak | 35 (69) | 17 (30) | 9 (18) | 35 (57) | 14 (26) | 2 (5) | ||
| Moderate | 14 (27) | 24 (42) | 16 (32) | 17 (28) | 24 (44) | 16 (37) | ||
| Strong | 2 (4) | 16 (28) | 25 (50) | 9 (15) | 16 (30) | 25 (58) | ||
| Recurrence | 0.009** | 0.180 | ||||||
| Absent | 45 (90) | 42 (76) | 29 (64) | 47 (78) | 42 (84) | 27 (68) | ||
| Present | 5 (10) | 13 (24) | 16 (36) | 13 (22) | 8 (16) | 13 (32) | ||
| Unknown | 1 | 2 | 5 | 1 | 4 | 3 | ||
χ2‐test: *P < 0.05, **P < 0.01. Each value is presented as number (%) of specimens. NS, not significant; SD, standard deviation.